2026-04-14
Phrontline Biopharma Presents Preclinical Data for TJ106, a Biparatopic HER2 Dual-Payload ADC, at AACR 2026
SHANGHAI, China, April 14, 2026 - Phrontline Biopharma today announced the presentation of preclinical data for TJ106, a next-generation biparatopic HER2-targeting antibody-drug conjugate (ADC) with a dual-payload platform, at the American Association for Cancer Research (AACR) Annual Meeting 2026.